scholarly journals Triiodothyronine-predominant Graves' disease in childhood: detection and therapeutic implications

2015 ◽  
Vol 172 (6) ◽  
pp. 715-723 ◽  
Author(s):  
Julie Harvengt ◽  
Priscilla Boizeau ◽  
Didier Chevenne ◽  
Delphine Zenaty ◽  
Anne Paulsen ◽  
...  
Keyword(s):  
Pediatric Population ◽  
Severe Disease ◽  
Antithyroid Drug ◽  
Rare Condition ◽  
University Hospital ◽  
Graves Disease ◽  
Therapeutic Implications ◽  
Group I ◽  
Median Serum ◽  
Group Ii

ObjectiveTo assess in a pediatric population, the clinical characteristics and management of triiodothyronine-predominant Graves' disease (T3-P-GD), a rare condition well known in adults, but not previously described in children.DesignWe conducted a university hospital-based observational study.MethodsAll patients with GD followed for more than 1 year between 2003 and 2013 (n=60) were included. T3-P-GD (group I) was defined as high free T3 (fT3) concentration (>8.0 pmol/l) associated with a normal free thyroxine (fT4) concentration and undetectable TSH more than 1 month after the initiation of antithyroid drug (ATD) treatment. Group II contained patients with classical GD without T3-P-GD.ResultsEight (13%) of the patients were found to have T3-P-GD, a median of 6.3 (3.0–10.5) months after initial diagnosis (n=4) or 2.8 (2.0–11.9) months after the first relapse after treatment discontinuation (n=4). At GD diagnosis, group I patients were more likely to be younger (6.8 (4.3–11.0) vs 10.7 (7.2–13.7) years) and had more severe disease than group II patients, with higher serum TSH receptor autoantibodies (TRAb) levels: 40 (31–69) vs 17 (8–25) IU/l, P<0.04, and with slightly higher serum fT4 (92 (64–99) vs 63 (44–83) pmol/l) and fT3 (31 (30–46) vs 25 (17–31) pmol/l) concentrations. During the 3 years following T3-P-GD diagnosis, a double dose of ATD was required and median serum fT4:fT3 ratio remained lower in group I than in group II.ConclusionSevere hyperthyroidism, with particularly high TRAb concentrations at diagnosis, may facilitate the identification of patients requiring regular serum fT3 determinations and potentially needing higher doses of ATD dosage during follow-up.

scholarly journals The Effect of Pregnancy on Subsequent Relapse from Graves’ Disease after a Successful Course of Antithyroid Drug Therapy

2008 ◽  
Vol 93 (10) ◽  
pp. 3985-3988 ◽  
Author(s):  
Mario Rotondi ◽  
Carlo Cappelli ◽  
Barbara Pirali ◽  
Ilenia Pirola ◽  
Flavia Magri ◽  
...  
Keyword(s):  
Positive Family History ◽  
Antithyroid Drug ◽  
Clinical Activity ◽  
Graves Disease ◽  
Clinical Relapse ◽  
Duration Of Treatment ◽  
Autoimmune Thyroid ◽  
Group I ◽  
Treatment Data ◽  
Group Ii

Objective: Pregnancy and the postpartum (PP) period are associated with profound changes of the immune system, which largely influence the clinical activity of autoimmune diseases. The aim of this study was to evaluate the effect of pregnancy and/or the PP period in driving a clinical relapse of hyperthyroidism in patients with Graves’ disease (GD) who are in remission after antithyroid drug (ATD) treatment. Data were retrospectively collected from 150 female patients with GD, who were assigned to two groups according to the occurrence of a successful pregnancy after ATD withdrawal. Results: Relapsing Graves’ hyperthyroidism was observed in 70 of 125 patients in group I (no pregnancy after ATD withdrawal) (56.0%) and 21 of 25 patients in group II (pregnancy after ATD withdrawal) (84.0%) (P &lt; 0.05). Logistic regression analysis (dependent variable: relapse/nonrelapse; covariates: age, positive family history for autoimmune thyroid disease, duration of treatment with ATD, number pregnancies at diagnosis, number of pregnancies after ATD withdrawal) showed a significant effect only for the number of pregnancies after ATD withdrawal [4.257 (1.315–13.782)]. The effect was ascribed to the PP period rather than to pregnancy itself because in 20 of 21 patients of group II (95.2%), the relapse of Graves’ hyperthyroidism occurred between 4 and 8 months after delivery. Conclusions: The PP period is significantly associated with a relapse of hyperthyroidism in GD patients being in remission after ATD. We therefore recommend that patients with GD in remission after a course of ATD should have their thyroid function tested at 3 and 6 months after delivery.

Antithyroid drug treatment of Graves' disease in pregnancy: Long-term effects on somatic growth, intellectual development and thyroid function of the offspring

1990 ◽  
Vol 123 (3) ◽  
pp. 311-316 ◽  
Author(s):  
Peter M. Messer ◽  
Berthold P. Hauffa ◽  
Thomas Olbricht ◽  
Georg Benker ◽  
Peter Kotulla ◽  
...  
Keyword(s):  
Drug Treatment ◽  
Thyroid Function ◽  
Intellectual Development ◽  
Antithyroid Drug ◽  
The Body ◽  
Graves Disease ◽  
Long Term Effects ◽  
Group I ◽  
Group Ii ◽  
Antithyroid Drug Treatment

Abstract. With regard to their thyroid function, somatic and intellectual development, we compared 17 children of 13 hyperthyroid mothers (group I) receiving antithyroid drug treatment during their pregnancies with 25 children of 15 mothers who were euthyroid without any antithyroid treatment during their pregnancy (group II). Mean duration of maternal treatment was 3.5 months in group I, using carbimazole or thiamazole (N=12) and propylthiouracil (N=1). Age at examination in group I was 7.2±6.2 years, in group II 8.7±7.1 years (mean±sd). Both groups showed no significant differences in the results of the clinical examination and in the degree of their mental and psychomotoric development at the time of study. We found the mean birth weight of the infants in group I significantly lower than in group II(3165±339 vs 3666±670 g, p<0.03). The individual birth weights, however, were normal for gestational age. The body weight difference between groups disappeared during the further somatic development of the children. The serum concentration of free thyroxine in group I was significantly higher than in group II (17.2 ± 2.4 vs 14.9±1.9 pmol/l, p<0.003), but fell in both groups within the normal range. The evaluation of the psychomotoric and intellectual capacity of the children at different developmental stages showed no abnormalities detectable by our tests. Thus, in the children of the two groups we found no adverse effects of a maternal antithyroid drug treatment during pregnancy or of inactive maternal Graves' disease alone, neither on thyroid gland size and function nor on the physical or intellectual development, after the neonatal period.

scholarly journals The prognostic role of inflammatory markers in COVID 19 patients – A retrospective analysis.

2021 ◽  
Author(s):  
Shivkumar Gopalakrishnan ◽  
sangeetha kandasamy ◽  
S.Malini ◽  
S.Peer Mohamed ◽  
k.velmurugan
Keyword(s):  
Inflammatory Markers ◽  
Severe Disease ◽  
Radiation Hazard ◽  
P Value ◽  
Binary Logistic Regression Analysis ◽  
Group Iii ◽  
Group I ◽  
Group Ii ◽  
D Dimer

Abstract Background. Approximately 5% of COVID-19 patients suffer near fatal disease. Clinical and radiologic features may predict severe disease albeit with limited specificity and radiation hazard. Laboratory biomarkers are eyed as simple, specific and point of care triage tools to optimize management decisions.This study aimed to study the role of inflammatory markers in prognosticating COVID-19 patients.Methodology. A hospital based retrospective study was conducted on COVID-19 adult inpatients classified into three groups as mild disease-recovered [Group I], severe disease-recovered [Group II] and dead [Group III]. Categorical outcomes were compared using Chi square test. Univariate binary logistic regression analysis was performed to test the association between the explanatory and outcome variables. Unadjusted OR along with 95% CI was calculated. The utility of lab parameters (Ferritin, LDH, D dimer, N/L ratio and PLT/L ratio) in predicting severity of COVID-19 was assessed by Receiver Operative Curve (ROC) analysis. P value < 0.05 was considered statistically significant.Results. The mean age was 49.32 +/- 17.1 years. Among study population, 378 were Group I, 66 Group II, and 56 Group III. Median levels of Ferritin among the 3 groups were 62ng/mL, 388.50 ng/mL and 1199.50 ng/mL. Median value of LDH were 95U/L, 720 and 982.50(p <0.001). D-dimer values of 3 groups were 23.20ng/mL, 104.30 ng/mL and 197.10 ng/mL (p <0.001). CRP done qualitatively was positive in 2 (0.53%), 30 (45.45%) and 53 (94.64%) of patients. The odds of patients suffering severe COVID-19 rose with rising values of ferritin, LDH and D-dimer [unadjusted OR 1.007, 1.004 &1.020]Conclusion. One time measurement of serum ferritin, LDH, D-dimer and CRP is promising to predict outcomes for COVID 19 inpatients. Single qualitative CRP was equally good but more cost effective than quantitative CRP. The most specific combination was NLR, Lymphocyte percentage and D-dimer levels done between 7th – 10th day of symptoms.

Familial Pityriasis Rubra Pilaris: Case Report and Review

2013 ◽  
Vol 17 (4) ◽  
pp. 226-232 ◽  
Author(s):  
Joshua M. Mercer ◽  
Chitra Pushpanthan ◽  
Canagasundrum Anandakrishnan ◽  
Ian D.R. Landells
Keyword(s):  
Autosomal Dominant ◽  
Pediatric Population ◽  
Severe Disease ◽  
Topical Therapy ◽  
Rare Condition ◽  
Unknown Etiology ◽  
Pityriasis Rubra Pilaris ◽  
Gradual Onset ◽  
Systemic Treatments ◽  
Appropriate Therapy

Background: Pityriasis rubra pilaris (PRP) is a rare dermatosis of unknown etiology. Most cases of PRP are sporadic; however, rare cases of familial PRP have been reported. Objectives: To present a case of PRP inherited in an autosomal dominant (AD) fashion and to evaluate the current literature on familial PRP and formulate a comprehensive, up-to-date summary of this rare condition. Methods: PubMed was used to conduct a search for articles pertaining to familial PRP published through May 2011. Results: The first documented case was published in 1910, and 36 subsequent familial cases of PRP have been reported. Familial PRP typically presents very early in childhood, has a gradual onset, and persists throughout life. Given the rarity of this subtype, determining the best therapy has been a challenge. In the pediatric population, a conservative treatment approach, including topical therapy, is frequently used, whereas systemic treatments are reserved for patients with a severe disease that is refractory to therapy. Conclusion: Rare cases of PRP inherited in an AD fashion have been described and tend to have a chronic clinical course and are treatment refractory. Therefore, the awareness of familial PRP is important for early and accurate diagnosis and administration of appropriate therapy.

scholarly journals COMPARATIVE STUDY BETWEEN THE EFFECT OF HISTAMINE RECEPTOR ANTAGONISTS OF TYPE II (FAMOTIDINE) AND PROTON PUMP INHIBITORS (OMEPRAZOLE) ON THE EFFICACY OF CALCIUM CARBONATE AS PHOSPHATE BINDER IN HAEMODIALYSIS PATIENT

2017 ◽  
Vol 9 (8) ◽  
pp. 10
Author(s):  
Hossam Aboelyazeed ◽  
Sahar El-haggar ◽  
Kamal Okasha
Keyword(s):  
Calcium Carbonate ◽  
Serum Calcium ◽  
Phosphate Binder ◽  
Renal Dialysis ◽  
University Hospital ◽  
Control Group ◽  
Group Iii ◽  
Group I ◽  
Group Ii ◽  
Pre Treatment

Objective: The purpose of this study was to compare the effect of famotidine versus omeprazole on the efficacy of calcium carbonate as a phosphate binder in the hemodialysis patient.Methods: From February 2014 to June 2014 a total number of 64 patients of both sexes were recruited from the department of renal dialysis, Tanta University Hospital, Egypt. Patients categorized into 3 groups. Group I (control group) consisted of 20 Patients (10) females and (10) males take calcium carbonate (caco3) (2.5–4 g/d) only, Group II consisted of 21 Patients (13) females and (8) males take the same dose of caco3 with famotidine 10 mg/d and Group III consisted of 23 Patients (8) females and (15) male take the same dose caco3 with omeprazole 20 mg/d.Results: All data are expressed as the mean±SD. Group II showed a significant increase (p<0.05) in serum phosphorus at 3rd mo with significant decreased (p<0.05) in serum calcium comparing with pre-treatment. Group III showed no significant change (p>0.05) in serum calcium, phosphorus and parathyroid hormone (PTH) comparing with pre-treatment. Both groups (II and III) showed a significant decrease in alkaline phosphatase (ALP) (p<0.05).Conclusion: Co-administration of famotidine with calcium carbonate aggravates hyperphosphatemia and this may increase the incidence of complications. The efficacy of calcium carbonate as a phosphate binder was not affected by co-administration of omeprazole.

scholarly journals SAT-413 Does Dipeptidyl Peptidase-4 Inhibitor Exacerbate Graves’ Disease?

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Tomonori Sekizaki ◽  
Hiraku Kameda ◽  
Kyu Yong Cho ◽  
Nakamura Akinobu ◽  
Kiyohiko Takahashi ◽  
...  
Keyword(s):  
Antithyroid Drug ◽  
Multivariate Logistic Regression Analysis ◽  
Dipeptidyl Peptidase ◽  
Drug Dose ◽  
University Hospital ◽  
Graves Disease ◽  
Dipeptidyl Peptidase 4 ◽  
Institutional Review ◽  
Baseline Characteristics ◽  
The Impact

Abstract Abstract: [Background] Dipeptidyl peptidase-4 (DPP-4) is expressed as CD26 on the surface of immune cells including T cells, suggesting that inhibition of DPP-4 may affect the immune system (1). Actually, DPP-4 inhibitor (DPP-4i)-induced polyarthritis and bullous pemphigoid have been reported (2, 3). It has also been reported that the prevalence of Hashimoto’s thyroiditis was significantly higher in patients on DPP-4i treatment (4). However, relationships between DPP-4i and Graves’ disease has been unclear. [Methods] To investigate the impact of DPP-4i administration on the activity of Graves’ disease, we conducted a multicenter observational trial that included patients with both Graves’ disease and type 2 diabetes mellitus who were administered an oral hypoglycemic agent (OHA) including DPP-4i from December in 2009 to April in 2018. Patients who had systemic diseases affecting thyroid function and those who underwent thyroidectomy or radioiodine treatment within 6 months before or after OHA administration were excluded. Exacerbation of Graves’ disease was defined as an increase in antithyroid drug dose within 6 months after OHA administration. The trial was approved by the institutional review board of Hokkaido University Hospital. [Results] Eighty-three patients were enrolled in the study, and they were divided into an exacerbation group (n = 18) and a non-exacerbation group (n = 65). Comparing baseline characteristics, the percentage of DPP-4i administration was higher in the exacerbation group (83.3%) than in the non-exacerbation group (32.3%) (p = 0.0001). Mean age was also significantly higher in the exacerbation group (p = 0.04), and the duration of Graves’ disease was significantly shorter (p = 0.01). Multivariate logistic regression analysis using factors extracted by comparing baseline characteristics demonstrated a significant association between DPP-4i administration and Graves’ disease exacerbation (odds ratio 5.62, 95% confidence interval 1.16–27.0, p = 0.02). [Conclusion] The current study suggests that DPP-4i administration is associated with exacerbation of Graves’ disease. Reference: (1) Morimoto C et al., Immunol Rev. 1998 Feb;161:55–70. (2) Yokota K et al., Intern Med. 2012;51(15):2041–4. (3) Yoshiji S et al. J Diabetes Investig. 2018 Mar;9(2):445–447. (4) Kridin K et al. Immunol Res. 2018 Jun;66(3):425–430.

Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine

1996 ◽  
Vol 134 (4) ◽  
pp. 454-456 ◽  
Author(s):  
Etienne Delgrange ◽  
Dominique Maiter ◽  
Julian Donckier
Keyword(s):  
Internal Medicine ◽  
Side Effects ◽  
Dopamine Agonist ◽  
Side Effect ◽  
University Hospital ◽  
The Third ◽  
Group I ◽  
Resistant Group ◽  
Group Ii ◽  
Long Acting

Delgrange E, Maiter D, Donckier J. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur J Endocrinol 1996;134:454–6. ISSN 0804–4643 Cabergoline is a new long-acting ergoline derivative used to treat hyperprolactinaemia. Its effect was assessed in 10 patients (eight women and two men) with prolactinoma who were intolerant (group I; N = 7) or resistant (group II; N = 3) to bromocriptine. In group I, no side effect was observed on cabergoline therapy; two patients became pregnant and normoprolactinaemia was achieved in the five others. In group II, cabergoline was active and well-tolerated in two out of the three patients: one woman had three consecutive pregnancies; in another patient normoprolactinaemia was restored and the tumour shrank by 60%; in the third patient cabergoline was discontinued because of side effects and inefficacy. Thus, cabergoline appears to be an alternative of choice as treatment of hyper-prolactinaemic patients who are intolerant or resistant to bromocriptine. Julian Donckier, Internal Medicine and Endocrinology, University Hospital UCL of Mont-Godinne, B-5530 Yvoir, Belgium

FAILURE OF THE TRH TEST TO PREDICT THE CLINICAL COURSE OF PATIENTS IN REMISSION AFTER ANTITHYROID DRUG THERAPY FOR GRAVES' DISEASE

1979 ◽  
Vol 90 (1) ◽  
pp. 18-22
Author(s):  
W. J. Irvine ◽  
R. S. Gray ◽  
A. D. Toft ◽  
J. Seth ◽  
E. H. D. Cameron
Keyword(s):  
Drug Therapy ◽  
Clinical Course ◽  
Antithyroid Drug ◽  
Normal Serum ◽  
Antithyroid Drugs ◽  
Trh Test ◽  
Group I ◽  
Antithyroid Drug Therapy ◽  
Group Ii ◽  
Serum Tsh

ABSTRACT In an attempt to assess the predictive value of the TRH test in patients in remission after stopping antithyroid drugs for thyrotoxicosis, 11 euthyroid patients with a subnormal (group I) and 23 euthyroid patients with a normal serum TSH response to TRH (group II) were followed-up for one year. The mean ± se intervals since the withdrawal of drug therapy were 23.2 ±1.6 and 20.4 ± 0.7 months, respectively, at the outset of the study. Five patients (45 %) from group I and 7 patients (30 %) from group II relapsed during the period of observation. In addition, a change from a subnormal to a normal serum TSH response to TRH and vice versa occurred in some patients. It is not possible to predict by means of the TRH test the subsequent clinical course of patients in remission following antithyroid drug therapy.

scholarly journals The Role of Platelet Indices in Prediction of Pre-eclampsia

2021 ◽  
pp. 69-77
Author(s):  
Walaa Abdelghafar Elbasuony ◽  
Hossam Abd el-mohsein Hodeib ◽  
Adel Elshahat Eljejawy ◽  
Karam Abd el-fattah Shaheen
Keyword(s):  
Obstetric Care ◽  
First Trimester ◽  
Diagnostic Value ◽  
University Hospital ◽  
Distribution Width ◽  
Platelet Indices ◽  
Group I ◽  
Gestational Week ◽  
First Trimester Of Pregnancy ◽  
Group Ii

Objective: The aim of this work is to investigate the diagnostic value of platelet count (PC), mean platelet volume (MPV), the PC to MPV ratio and platelet distribution width (PDW) for prediction of pre-eclampsia (PE). Subjects and Methods: This prospective cohort study included 100 pregnant women, in the first trimester of pregnancy attending to University Hospital, Obstetric Outpatient Clinic, for routine obstetric care from January 2019 to December 2019. Routine obstetric follow-up consists of monthly visits until 32nd gestational week, bimonthly visits between 32nd and 36th gestational week, and weekly thereafter. Patients were classified into two groups: group I: 9 pre-eclamptic patients and group II: non pre-eclamptic 91 patients. CBC indices were measured at each planned visit Results: PC, PC/MPV were significantly decreased, MPV and PDW were significantly increased in group I than group II at the 2nd part of pregnancy. To predict pre-eclampsia, PC at cut-off ≤214, sensitivity was 77.78, specificity was 76.92. MPV at cut-off >9.7, sensitivity was 77.78, specificity was 100.00, PC-MPV at cut-off ≤26.89, sensitivity was 88.89, specificity was 78.02. PDW at cut-off >10.4, sensitivity was 88.89, specificity was 54.95. Conclusion: The increase in the MPV and PDW and the decrease in PC and PC/MPV were observed in preeclampsia. Thus, the platelet indices which are easily available, as well as economical, can also be used in the prediction and early diagnosis of preeclampsia.

scholarly journals Endocrine Dysfunction in Covid-19

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A627-A628
Author(s):  
Liza Das ◽  
Pinaki Dutta ◽  
Sanjay Kumar Bhadada ◽  
Ashu Rastogi ◽  
Rama Walia ◽  
...  
Keyword(s):  
Oxygen Saturation ◽  
Disease Severity ◽  
Severe Disease ◽  
Male Hypogonadism ◽  
Endocrine Dysfunction ◽  
Low T3 Syndrome ◽  
Group I ◽  
Low T3 ◽  
Endocrine Organs ◽  
Group Ii

Abstract Introduction: Evidence pertaining to new-onset endocrine dysfunction in patients with COVID-19 is currently limited and extrapolated from prior SARS epidemics. Further, identifying whether the quantum of this dysfunction is associated with the severity of disease in patients with COVID-19 is unknown. We aimed to to comprehensively explore the prevalence, nature and degree of endocrine dysfunction stratified based on disease severity at a dedicated COVID care centre. Patients and Methods: Consecutive patients enrolled at PGIMER Chandigarh, were stratified on the basis of disease severity as: group I (moderate to severe disease including oxygen saturation &lt;94% on room air or those with comorbidities) and group II (mild disease, with oxygen saturation &gt;94% and without comorbidities). Hypothalamo-pituitary-adrenal, thyroid, gonadal axes and lactotroph function were evaluated. Inflammatory and cell-injury markers were also analysed. Results: Patients in group I had higher prevalence of hypocortisolism (38.5 vs 6.8%, p=0.012), lower ACTH (16.3 vs 32.1pg/ml, p=0.234) and DHEAS (86.29 vs 117.8µg/dl, p= 0.086) as compared to group II. Low T3 syndrome was a universal finding, irrespective of disease severity. Sick euthyroid syndrome (apart from low T3 syndrome) (80.9 vs 73.1%, p= 0.046) and atypical thyroiditis (low T3, high T4, low or normal TSH) (14.3 vs 2.4%, p= 0.046) were more frequent in group I than group II. Male hypogonadism was also more prevalent in group I (75.6% vs 20.6%, p=0.006) than group II, with higher prevalence of both secondary (56.8 vs 15.3%, p=0.006) and primary (18.8 vs 5.3%, p=0.006) hypogonadism. Hyperprolactinemia was observed in 42.4% patients, without significant difference between both groups. Conclusion: COVID-19 can involve multiple endocrine organs and axes, with a greater prevalence and degree of endocrine dysfunction in those with more severe disease. Involvement of multiple axes, particularly at hypothalamo-pituitary level suggests the possibility of hypophysitis as an underlying etiology. We also observed less characterised findings like atypical thyroiditis and normal DHEAS despite secondary hypocortisolism. Follow-up surveillance of these patients at periodic intervals and estimation of anti-pituitary antibodies could be considered to elucidate viral cytopathic effect or inflammation as the major underlying mechanism of endocrine dysfunction.

Sign in / Sign up

Export Citation Format

Share Document